Key result
Mesenchymal precursor cells miss primary endpoints but may improve HF outcomes in patients with inflammation.
Why the study?
Does targeted transendocardial mesenchymal precursor cell therapy improve outcomes in patients with heart failure?
Does targeted transendocardial mesenchymal precursor cell therapy improve outcomes in patients with heart failure?
Targeted transendocardial mesenchymal precursor cell therapy did not meet primary or secondary endpoints in heart failure patients, though exploratory analyses suggest potential benefit in those with inflammation.
Should not change heart failure practice; leaves open targeted benefit of mesenchymal precursor cells in inflamed patients.
The primary and secondary endpoints of the trial were negative. Positive signals in prespecified, and post hoc exploratory analyses suggest MPCs may improve outcomes, especially in patients with inflammation.
No takes yet. Share an insight, caveat, or question.
Perin et al. (2023) studied this question. Mesenchymal precursor cells may improve outcomes in heart failure patients, particularly those with inflammation, despite negative primary and secondary endpoints.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: